Real‐World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: <scp>GLP</scp> ‐1 Receptor Agonists Versus <scp>FDA</scp> ‐Approved <scp>AUD</scp> Medications
GLP-1RAs are a promising option for patients with concurrent MetD and AUD, improving relapse rates and metabolic outcomes compared with currently FDA-approved pharmacotherapies for AUD. Trends toward better liver outcomes support further prospective evaluation.
Authors
- Paul Y. Kwo (ORCID: https://orcid.org/0000-0002-8234-4485)
- Gavin Hui (ORCID: https://orcid.org/0000-0002-4818-4254)
- Saurabh Gombar (ORCID: https://orcid.org/0000-0002-5581-8569)
- William Pike
- Amir Gougol
- Mehdi Farokhnia (ORCID: https://orcid.org/0000-0003-0902-4212)
- Babak Mirminachi
Institutions
- Indiana University Health (US)
- National Institute on Drug Abuse (US)
- Palo Alto University (US)
- National Institute on Alcohol Abuse and Alcoholism (US)
- University of Pittsburgh Medical Center (US)
- Stanford University (US)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1111/apt.70596
- Primary Topic
- Alcohol Consumption and Health Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00